Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study-Reference-Cited by-同舟云学术

Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study

Published:2008-01 Issue:2 Volume:49 Page:306-314
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Liu Hong,Yuan Constance,Heinerich Jeremy,Braylan Raul,Chang Myron,Wingard John,Moreb Jan

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428190701813018

Reference38 articles.

1. Stem Cell Transplantation for Multiple Myeloma

2. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma

3. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma

4. Minimal residual disease monitoring in multiple myeloma

5. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma;Cancer Medicine;2023-04-11

2. The role of surface molecule CD229 in Multiple Myeloma;Clinical Immunology;2019-07

3. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis;Annals of Hematology;2019-02-05

4. IMMUNOPHENOTYPE OF BONE MARROW PLASMA CELLS IN PATIENTS WITH MULTIPLE MYELOMA DURING HIGH-DOSE CHEMOTHERAPY AND AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION;GEMATOL TRANSFUZIOL;2017

5. Immunotherapies targeting CD38 in Multiple Myeloma;OncoImmunology;2016-08-05